KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Share-based Compensation: 2015-2024

Historic Share-based Compensation for Palvella Therapeutics (PVLA) over the last 10 years, with Dec 2024 value amounting to $268,000.

  • Palvella Therapeutics' Share-based Compensation rose 111.68% to $268,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $830,000, marking a year-over-year increase of 37.65%. This contributed to the annual value of $830,000 for FY2024, which is 37.65% up from last year.
  • Latest data reveals that Palvella Therapeutics reported Share-based Compensation of $268,000 as of Q4 2024, which was up 34.67% from $199,000 recorded in Q3 2024.
  • Over the past 5 years, Palvella Therapeutics' Share-based Compensation peaked at $1.4 million during Q3 2020, and registered a low of -$2.3 million during Q4 2023.
  • Its 3-year average for Share-based Compensation is $486,250, with a median of $916,500 in 2022.
  • In the last 5 years, Palvella Therapeutics' Share-based Compensation tumbled by 341.83% in 2023 and then soared by 111.68% in 2024.
  • Quarterly analysis of 5 years shows Palvella Therapeutics' Share-based Compensation stood at $1.2 million in 2020, then grew by 12.44% to $1.3 million in 2021, then fell by 28.11% to $949,000 in 2022, then plummeted by 341.83% to -$2.3 million in 2023, then soared by 111.68% to $268,000 in 2024.
  • Its Share-based Compensation was $268,000 in Q4 2024, compared to $199,000 in Q3 2024 and $217,000 in Q2 2024.